[研究报告] 皮肤科OTC药物市场预计将从2021年的154.5663亿美元增长到2028年的213.1340亿美元;预计2021年至2028年的复合年增长率为4.7%。
皮肤科非处方药直接销售给消费者,无需医疗保健专业人员的处方,而处方药则只能销售给持有有效处方的消费者。非处方药由监管机构挑选,以确保其所含成分在无需医生指导的情况下使用时是安全有效的。非处方药通常根据其活性药物成分 (API) 而不是最终产品进行监管。通过监管 API 而不是特定药物配方,政府允许制造商自由地将成分或成分组合配制成专有混合物。
皮肤科非处方药市场根据产品类型、给药途径、适应症、分销渠道和地理位置进行细分。按地理位置划分,市场大致分为北美、欧洲、亚太地区、中东和非洲 (MEA) 以及南美和中美。该报告提供了对市场的深入分析和见解,强调了市场趋势、技术进步和市场动态等参数,以及对世界主要市场参与者的竞争格局的分析。
定制此报告以满足您的需求
您可以免费定制任何报告,包括本报告的部分内容、国家级分析、Excel 数据包,以及为初创企业和大学提供优惠和折扣
- 获取此报告的关键市场趋势。这个免费样品将包括数据分析,从市场趋势到估计和预测。
市场洞察
皮肤问题高发推动皮肤科非处方药市场增长
皮肤问题的高发性和中产阶级收入的增加预计将推动全球市场的增长。然而,非处方药的不当使用正在抑制皮肤科非处方药市场的增长。皮肤问题,如色素沉着、皱纹、皱纹、痤疮和烧伤疤痕,在人们中很常见。根据美国皮肤病学会 (AADA) 的数据,痤疮是美国最常见的皮肤病,每年影响约 5000 万美国人。此外,约 85% 的 12 至 24 岁人群患有轻微痤疮问题。2013 年,接受痤疮治疗的患者与痤疮治疗相关的费用和生产力损失超过约 12 亿美元;同年,超过约 510 万人(主要是儿童和年轻人)因痤疮寻求医疗治疗。此外,根据 AADA 的数据,十分之一的人患有特应性皮炎,影响多达 25% 的儿童和 2-3% 的成人。 2021 年,根据 Dermstore 对美国 2,000 名女性进行的一项民意调查,年轻女性比年长女性更早开始使用产品来减少衰老迹象。此外,欧盟委员会 (EC) 将皮肤病列为人类疾病的第四大常见原因。寻常痤疮在多个国家越来越普遍。皮肤科非处方药被广泛用于治疗痤疮。了解寻常痤疮负担的特征对于开发有效且有针对性的痤疮控制疗法至关重要。根据 2019 年全球疾病负担研究,全球报告了 1.174 亿寻常痤疮新发病例、2.312 亿患病病例和 500 万伤残调整生命年 (DALY),自 1990 年以来增长了 48%。
皮肤病意识的提高对市场增长有重大贡献
皮肤病严重影响发展中国家人民的生活质量,导致工作和学习效率下降,并因毁容而受到歧视。皮肤变化也可能表明存在需要治疗的更严重的疾病。以前,卫生官员忽视或不重视此类疾病,因为它们在大多数情况下不会危及生命,而且在三级医疗中心很少见到。
目前,国家和国际医疗中心必须培训发展中国家的医疗保健工作者,以提高皮肤病的诊断和治疗水平。
美国皮肤病学会 (AAD) 已启动多项公共宣传计划,以改善皮肤、头发和指甲的外观。例如,十月是湿疹宣传月,AAD 提供皮肤科医生认可的信息,帮助人们更好地了解和管理湿疹。美国皮肤协会 (ASA) 2021 年的资助方案现已推出,用于支持杰出的皮肤病研究人员和医生。在过去的 34 年里,ASA 资助了数百项资助,这些资助带来了重要的皮肤病学突破,并提高了人们对皮肤病的认识和了解。因此,对皮肤病的认识不断提高,支持了皮肤科非处方药市场的增长。
产品类型洞察
根据产品类型,全球皮肤科非处方药市场分为片剂和胶囊、凝胶、乳膏和软膏等。2021 年,乳膏和软膏占据了最大的市场份额。然而,预计片剂和胶囊市场在预测期内的复合年增长率最高。
给药途径洞察
根据给药途径,皮肤科非处方药市场分为外用和口服。2021 年,外用部分占据了较大的市场份额;然而,预计口服部分在预测期内的复合年增长率会更高。
指示见解
根据适应症,皮肤科非处方药市场细分为皮炎、痤疮、牛皮癣、皮肤白化、真菌病、疣等。痤疮领域在 2021 年占据了最大的市场份额;预计在预测期内将录得最高的复合年增长率。
分销渠道洞察
根据分销渠道,皮肤科非处方药市场分为线上分销和线下分销。线下分销部分在 2021 年占据了更大的市场份额;然而,预计在线分销部分在预测期内的复合年增长率会更高。此外,线下分销部分分为零售和医院药店以及超市和大卖场。零售和医院药店部分在 2021 年占据了更大的市场份额。
产品发布、合并和收购是全球皮肤科非处方药市场参与者最常采用的策略。以下列出了一些近期的关键产品开发:
2020 年 8 月,全球领先的优质实惠个人护理产品供应商 Perrigo Company plc 宣布从赛诺菲收购了三个东欧 OTC 护肤和脱发治疗品牌(Emolium、Iwostin 和 Loxon)。
2018 年 4 月,Sol-Gel Technologies Ltd. 是一家临床阶段皮肤病学公司,专注于识别、开发和商业化用于治疗皮肤病的品牌和仿制外用药物产品,该公司宣布已与 Perrigo Company plc 的附属公司 Perrigo Israel 合作开发、制造和商业化仿制候选产品。
COVID-19 疫情给全球医疗保健行业带来了沉重的负担。随着世界缓慢复苏,企业的经营方式将永远不会再一样。COVID-19 改变了整个企业格局。几家公司在 2019 年最后一个季度遭受了严重损失,并对 2020 年第一季度和第二季度产生了负面影响。为确定 SARS-CoV-2 病毒对患者的威胁而开展的研究和开发活动可能会减缓皮肤科非处方药市场的增长。因此,COVID-19 疫情对皮肤科非处方药市场的影响是立竿见影的。由于医疗保健的重点转向拯救生命,COVID-19 疫情导致对皮肤科非处方药的需求减少。COVID-19 疫情正在对全球供应链、消费市场和全球经济造成巨大破坏。由于世界各国政府采取的措施,对皮肤科非处方药的需求可能会暂时大幅下降。因此,疫情对皮肤科非处方药市场产生了不利影响。
皮肤科非处方药 – 市场细分
全球皮肤科非处方药市场根据类型、技术、服务和地域进行细分。根据产品类型,市场细分为片剂和胶囊、凝胶、乳膏和软膏等。根据给药途径,皮肤科非处方药市场分为外用和口服。根据适应症,皮肤科非处方药市场细分为皮炎、痤疮、牛皮癣、皮肤漂白、真菌病、疣等。根据分销渠道,市场分为线上分销和线下分销。根据地域,皮肤科非处方药市场大致分为北美、欧洲、亚太地区、中东和非洲以及南美和中美洲。
皮肤科非处方药市场区域洞察
Insight Partners 的分析师已详尽解释了预测期内影响皮肤科非处方药市场的区域趋势和因素。本节还讨论了北美、欧洲、亚太地区、中东和非洲以及南美和中美洲的皮肤科非处方药市场细分和地理位置。
- 获取皮肤科非处方药市场的区域特定数据
皮肤科非处方药市场报告范围
报告属性 | 细节 |
---|---|
2021 年市场规模 | 154.6亿美元 |
2028 年市场规模 | 213.1亿美元 |
全球复合年增长率(2021 - 2028) | 4.7% |
史料 | 2019-2020 |
预测期 | 2022-2028 |
涵盖的领域 | 按产品类型
|
覆盖地区和国家 | 北美
|
市场领导者和主要公司简介 |
|
市场参与者密度:了解其对商业动态的影响
皮肤科非处方药市场正在快速增长,这得益于终端用户需求的不断增长,而这些需求又源于消费者偏好的不断变化、技术进步以及对产品优势的认识不断提高等因素。随着需求的增加,企业正在扩大其产品范围,进行创新以满足消费者的需求,并利用新兴趋势,从而进一步推动市场增长。
市场参与者密度是指在特定市场或行业内运营的企业或公司的分布情况。它表明在给定市场空间中,相对于其规模或总市场价值,有多少竞争对手(市场参与者)存在。
在皮肤科非处方药市场运营的主要公司有:
- 博士伦保健公司
- 百利高公司
- 拜耳公司
- Viatris 公司
- 强生服务公司
免责声明:上面列出的公司没有按照任何特定顺序排列。
- 获取皮肤科非处方药市场顶级关键参与者概述
公司简介
- 博士伦保健公司
- 百利高公司
- 拜耳公司
- Viatris 公司
- 强生服务公司
- 利奥制药公司
- 葛兰素史克公司
- 高德美
- 雷迪博士实验室
- ACELLA 制药有限公司
- Historical Analysis (2 Years), Base Year, Forecast (7 Years) with CAGR
- PEST and SWOT Analysis
- Market Size Value / Volume - Global, Regional, Country
- Industry and Competitive Landscape
- Excel Dataset
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
The dermatology OTC medications market majorly consists of the players such as, Bausch Health Companies Inc.; Perrigo Company plc; Bayer AG; Viatris Inc.; Johnson and Johnson Services, Inc.; LEO Pharma A/S; GlaxoSmithKline plc.; Galderma; Dr. Reddy's Laboratories; and Acella Pharmaceuticals, LLC.
Dermatology OTC medicines are directly sold by pharmacies and drug stores without the prescription from the physicians, as opposed to the drugs prescribed and maybe only sold to consumers who hold a valid prescription.
Several factors are believed to affect dermatology OTC medications market in the coming years. Factors such as high prevalence of skin problems and rising income of middle-class population are expected to boost the dermatology OTC medications market. However, the market is likely to get impacted by inappropriate use of OTC medications during the forecast period.
The global dermatology OTC medications market-based product type, market is categorized into tablets & capsules, gels, creams & ointments, and others. The creams and ointments segment held the largest share of the market in 2021. However, the tablets and capsules segment is anticipated to register the highest CAGR during the forecast period.
The global dermatology OTC medications market is segmented into North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America. The US holds the largest share of the market in this region. The market growth in the country is attributed to the increase in skin abnormalities and the rise of availability of medication for dermatology over the counter (OTC) in the region.
The Asia Pacific region is expected to account for the fastest growth in the dermatology OTC medications market. In Japan, India and South Korea, the market is expected to grow owing to the ongoing research activities related to dermatology OTC products in the region.
Trends and growth analysis reports related to Life Sciences : READ MORE..
The List of Companies - Dermatology OTC Medications Market
- Bausch Health Companies Inc.
- Perrigo Company plc
- Bayer AG
- Viatris Inc.
- Johnson and Johnson Services, Inc.
- LEO Pharma A/S
- GlaxoSmithKline plc.
- Galderma
- Dr. Reddy's Laboratories
- Acella Pharmaceuticals, LLC
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.